You are viewing: India Antibody Therapeutics Market analysis
Part of: Antibody Therapeutics Market (Global)

The India Antibody Therapeutics Market was valued at $830 Million in 2026 and projected to reach to $1280 Million by 2031, representing a compound annual growth rate of 4.9%. India's antibody therapeutics market is positioned as a critical growth segment within the Asia Pacific region, driven by escalating chronic disease burden and expanding healthcare infrastructure.

India Antibody Therapeutics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Antibody Therapeutics Market Trends and Insights

  • The market in India is expected to expand to USD 1,280 million by 2031, reflecting a compound annual growth rate (CAGR) of 4.9%.
  • This growth trajectory in India is driven by increasing prevalence of chronic diseases, rising healthcare expenditure, and expanding biopharmaceutical manufacturing capabilities.
  • India's role as a global hub for biologics production and contract manufacturing further strengthens the antibody therapeutics market landscape. The antibody therapeutics sector in India benefits from a growing patient population, improved access to advanced therapies, and supportive regulatory frameworks.
  • India's pharmaceutical industry expertise and cost-competitive manufacturing advantage position the country as an attractive market for both domestic and international antibody-based therapeutics.
  • Between 2026 and 2031, India is expected to witness increased adoption of monoclonal antibodies and other antibody-based treatments across oncology, immunology, and infectious disease segments.
  • Strategic investments in research and development infrastructure across India continue to enhance the market's competitive positioning within the broader Asia Pacific antibody therapeutics ecosystem..

Key Market Statistics

  • CAGR (2026-2031) 4.9% CAGR
  • Market Size, 2026 ~USD 830 Million
  • Forecast, 2031 ~USD 1280 Million
  • Country India

India Antibody Therapeutics Market Overview

Market Valuation Growth :

India's antibody therapeutics market is valued at USD 830 million in 2026 and is projected to reach USD 1,280 million by 2031, demonstrating strong expansion potential in the South Asian healthcare sector.

Steady CAGR Performance :

The Indian market is growing at a CAGR of 4.9% from 2026 to 2031, outpacing many emerging markets and reflecting increasing adoption of advanced therapeutic solutions across the country.

Chronic Disease Prevalence :

Rising incidence of chronic diseases including cancer, autoimmune disorders, and cardiovascular conditions in India is driving demand for targeted antibody-based therapeutics and personalized treatment options.

Healthcare Infrastructure Expansion :

Increasing healthcare expenditure and modernization of medical facilities across Indian metros and tier-2 cities are enabling greater accessibility to antibody therapeutics for patient populations.

India Antibody Therapeutics Market Dynamics

  • The market's 4.9% CAGR reflects growing physician adoption of monoclonal antibodies and immunotherapies, supported by improving reimbursement policies and increased awareness among healthcare providers. The forecast period through 2031 will witness accelerated market penetration as biosimilar antibodies gain traction, reducing treatment costs and improving patient accessibility.
  • Government initiatives promoting domestic biopharmaceutical manufacturing and rising private sector investments will further strengthen India's position as a key hub for antibody therapeutics development and commercialization in the region..

Market Ecosystem

logo-mobile

ANTIBODY THERAPEUTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Administered teclistamab, a BCMA×CD3 bispecific antibody for relapsed/refractory multiple myeloma, using a hospital-based step-up dosing model. Supports safe administration of complex bispecific antibodies, reduces serious toxicity risk through specialist monitoring, and creates a practical hospital-to-clinic care pathway for high-value antibody therapeutics.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • India's antibody therapeutics market is valued at USD 830 million in 2026 and is projected to reach USD 1,280 million by 2031, growing at a CAGR of 4.9%.
    • India's position as a global biopharmaceutical manufacturing hub and cost-competitive producer drives significant market expansion for antibody-based therapeutics.
    • Rising chronic disease prevalence and increased healthcare spending in India are key catalysts accelerating antibody therapeutics adoption across multiple therapeutic areas.
    • Strategic R&D investments and supportive regulatory policies in India are enhancing the country's competitive advantage in the antibody therapeutics market through 2031.

    Antibody Therapeutics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment PIPELINE PRODUCTS (Product)
    Forecast Period 2026-2031
    Growth Rate CAGR of 7.5% from 2026 to 2031
    Largest Segment COMMERCIALIZED PRODUCTS (Product)
    Market Size Base Year (Billions) ~USD 311.44 (2026)
    Revenue Forecast (Billions) ~USD 447.11 (2031)
    Segments Covered Product, Type, Format, Payload Type, Target, Source, Route Of Administration, Therapeutic Area, End User

    India Antibody Therapeutics Market Report Segmentation

    9 segment dimensions are covered across the global market.

    By Product

    • Commercialized Products
    • Pipeline Products

    By Type

    • Darzalex
    • Dupixent
    • Ivonescimab
    • Izalontamab Brengitecan
    • Keytruda
    • Other Commercialized Products
    • Other Pipeline Products
    • Sacituzumab Tirumotecan (Sac-Tmt)
    • Skyrizi
    • Vyvgart

    By Format

    • Antibody Drug Conjugates (Adcs)
    • Antibody Fragments
    • Antibody-Drug Conjugates
    • Bispecific Antibodies
    • Monoclonal Antibodies
    • Other Antibody Therapeutics
    • Other Formats
    • Polyclonal Antibodies

    By Payload Type

    • Dm1
    • Dm4
    • Mmae
    • Other Payload Types
    • Sn-38

    By Target

    • Cytokine/Inflammatory Pathway Targets
    • Her2
    • Other Targets
    • Pd-1/Pd-L1
    • Tnf Alpha

    By Source

    • Chimeric
    • Human
    • Humanized
    • Other Sources

    By Route Of Administration

    • Intravenous
    • Other Routes Of Administration
    • Subcutaneous

    By Therapeutic Area

    • Autoimmune & Inflammatory Diseases
    • Bone Disorders
    • Hematology
    • Immunology
    • Infectious Diseases
    • Neurology
    • Oncology
    • Osteology
    • Other Therapeutic Areas

    By End User

    • Hospitals & Specialty Care Centers
    • Long-Term Care Facilities
    • Other End Users

    Target Audience

    • Pharmaceutical Companies : Biopharmaceutical manufacturers and global pharma firms need India-specific market data to evaluate market entry strategies, pricing models, and commercial viability for antibody therapeutics.
    • Healthcare Investors : Private equity firms and venture capital investors require detailed India market analysis to assess investment opportunities in antibody therapeutics companies and healthcare infrastructure.
    • Medical Device & Biotech Firms : Companies developing complementary diagnostics and delivery systems need insights into India's antibody therapeutics adoption rates and healthcare provider preferences.
    • Healthcare Consultants : Management consulting firms advising healthcare clients require comprehensive India market data to support strategic planning, market positioning, and competitive benchmarking.
    • Government & Policy Bodies : Indian healthcare regulators and policy makers need market intelligence to inform biosimilar policies, pricing regulations, and healthcare infrastructure development initiatives.

    Reasons to Buy this Report

    • India-Specific Market Sizing : Access precise valuation data for India's antibody therapeutics market with detailed forecasts through 2031, enabling accurate business planning and investment decisions tailored to the Indian healthcare landscape.
    • Competitive Landscape Analysis : Understand key players, market consolidation trends, and competitive positioning specific to India's antibody therapeutics sector to identify partnership and acquisition opportunities.
    • Regulatory & Reimbursement Insights : Gain comprehensive understanding of India's regulatory framework, pricing policies, and reimbursement mechanisms affecting antibody therapeutics commercialization and market access strategies.
    • Growth Driver Identification : Identify and analyze India-specific growth catalysts including chronic disease prevalence, healthcare spending patterns, and biosimilar adoption rates driving market expansion.
    • Strategic Market Entry Planning : Develop informed market entry strategies with actionable insights on distribution channels, healthcare provider networks, and patient demographics across Indian regions.

    Frequently asked questions

    What is the current market size of antibody therapeutics in India?

    India's antibody therapeutics market is valued at USD 830 million in 2026 and is expected to grow to USD 1,280 million by 2031.

    What is the projected CAGR for India's antibody therapeutics market?

    India's antibody therapeutics market is projected to grow at a compound annual growth rate (CAGR) of 4.9% from 2026 to 2031.

    What factors are driving growth in India's antibody therapeutics market?

    Key growth drivers in India include rising chronic disease prevalence, increasing healthcare expenditure, expanding biopharmaceutical manufacturing capabilities, and supportive regulatory frameworks for biologics.

    Why is India significant in the global antibody therapeutics market?

    India serves as a global hub for cost-competitive biopharmaceutical manufacturing and contract manufacturing, making it a strategic location for antibody therapeutics production and distribution.

    Which therapeutic areas are driving antibody therapeutics adoption in India?

    Oncology, immunology, and infectious disease segments are primary therapeutic areas driving antibody therapeutics adoption and market growth in India.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global antibody therapeutics market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.

    Secondary Research

    Secondary research was used primarily to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, the World Health Organization (WHO), the United States Food and Drug Administration (US FDA), the National Center for Biotechnology Information (NCBI), and regulatory body websites, among others. These sources also provided key information on major players, market classification, and segmentation aligned with industry trends, regional and country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Antibody Therapeutics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the antibody therapeutics market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

    Antibody Therapeutics Market : Top-Down and Bottom-Up Approach

    Antibody Therapeutics Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size through the estimation process, the total market was segmented into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Therapeutic antibodies are targeted biopharmaceuticals that trigger a biological response. Therapeutic antibodies are drugs that use antibodies, which play a significant role in the body's innate immune system. Antibodies are produced by B cells, a type of immune cell, to attack foreign substances (antigens) in response to infections or allergens. Since antibodies recognize and attack only specific antigens, these properties are leveraged to generate genetically engineered antibodies (chimeric, humanized, fully human, engineered fragments & bispecific) designed to target and neutralize specific disease markers.

    Key Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty care centers
    • Regulatory agencies
    • Health insurers and payers
    • Private and government-funding organizations

    Report Objectives

    • To define, describe, and forecast the global antibody therapeutics market by product, format, target, source, route of administration, therapeutic area, end user, and region
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall antibody therapeutics market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
    • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically analyze the market structure and profile the key players of the global antibody therapeutics market, and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the antibody therapeutics market

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

    Portfolio Assessment

    • Product Matrix gives a detailed comparison of the product portfolios of the top five companies

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Geographical Analysis

    • Further breakdown of the Rest of Europe market, by country
    • Further breakdown of the Rest of Asia Pacific market, by country

     

    Get the Full Antibody Therapeutics Market Report

    Full forecast, segment splits, and company analysis for all Antibody Therapeutics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status